Is JAK Inhibitor A Therapeutic Option For Endometriosis?

Abstract

Endometriosis is a prevalent gynecological disorder that often leads to infertility and presents a complex challenge in its diagnosis and management. This report describes a case history of a 38-year-old woman suffering from rheumatoid arthritis and primary infertility who became pregnant after the initiation of tofacitinib treatment for rheumatoid arthritis. Her disease activity was well-controlled, and she became pregnant six months after the initiation of tofacitinib. We could not find any earlier reports of pregnancy in humans following tofacitinib treatment for endometriosis-related infertility in the literature. This observation suggests a potential link between the JAK pathway, inflammation associated with endometriosis and fertility. Although promising, cautious exploration of the possibility with large controlled studies are essential to validate these findings and assess the safety and efficacy of JAK inhibitors in endometriosis treatment.